JuniorSTAR™ insulin pen designed to help young people living with diabetes take greater control of their lives

JuniorSTAR™ insulin pen designed to help young people living with diabetes 
take greater control of their lives 
MONTREAL, July 2, 2014 /CNW/ - Kids with Type 1 Diabetes (T1D) face many 
difficulties and challenges, including learning to self-inject. But now a new 
insulin pen from Sanofi Canada has been designed to help these youngsters 
through the process. 
JuniorSTAR(™), available across Canada, has been developed for ease of use. 
A recent survey found that JuniorSTAR(™) is well suited to the lifestyle of 
young people with T1D and "could help them to gain autonomy to self-inject."(1) 
This is important, since controlling their T1D is the first step in enabling 
people to become empowered. "These kids go through a lot - emotionally, 
socially, and psychologically," said Martin Arès, Sanofi Canada's 
Vice-President, Diabetes Patient-Centered Unit. "By making it easier for them 
to manage, giving them greater control, JuniorSTAR(™) can make a positive 
In Canada, more than 300,000 individuals have T1D and the number is growing 
every year.(2) T1D usually develops in childhood or adolescence.(3) It is an 
autoimmune disease in which the body's immune system attacks and destroys the 
insulin-producing cells of the pancreas, thereby leaving the individual 
dependent on an external source of insulin for life. 
Living with T1D requires constant vigilance. People with the disease must 
carefully balance insulin doses (either by injections multiple times a day or 
continuous infusion through a pump) with eating and daily activities. They 
must also test their blood sugar by pricking their fingers six or more times a 
day. Despite this constant attention, people with T1D still run the risk of 
dangerously high or low blood sugar levels, both of which can be 
life-threatening.(4) * 
____________________________ (1) Klonoff D et al., Evaluation of the 
JuniorSTAR® Half-unit Insulin Pen in Young People with Type 1 Diabetes - User 
Perspectives, European Endocrinology, 2013; 9(2):82-5 (2) Canadian Diabetes 
Association, The prevalence and costs of diabetes, December 2009.  (3) 
Canadian Diabetes Association 
http://www.diabetes.ca/documents/get-involved/WEB_Eng.CDA_Report_.pdf (4) JDRF 
http://www.jdrf.ca/news-and-media/fact-sheets/type-1-diabetes/ * As per the 
CDA guidelines: For individuals using insulin more than once a day, SMBG 
should be measured as an essential part of diabetes self-management and should 
be undertaken at least 3 times per day and include both pre- and postprandial 
measurements. http://guidelines.diabetes.ca/executivesummary/ch9#bib1 
For parents and young patients, especially, T1D can be overwhelming. "It 
definitely has a big impact on their lives and emotional well-being," 
explained Marlene Grass RN, a Nurse Educator in Durham Region specializing in 
T1D. "They may be self-conscious, worried about body image, feeling socially 
excluded, angry and may have depressed feelings. It may affect how well they 
do in school. It has an impact on their family and caregivers as well." 
She added: "That's why it's so important to empower these youngsters, to help 
them gain greater independence in performing their diabetes procedures, under 
adult supervision, and having a feeling of more control over their lives. It 
is also reassuring for parents who are very concerned about the health and 
wellbeing of their children. JuniorSTAR(™ )is an insulin injection pen that 
helps facilitate this." 
The key features of JuniorSTAR(™) are: 

    --  doses can be adjusted in half-units - meeting the requirements
        of younger patients
    --  the dosage display is large - easy to read
    --  it's lightweight (only 34 grams) - easy to carry
    --  the outer body is made of aluminum - can withstand kids' active
    --  there are two different coloured pens - to help avoid insulin
    --  there is a single step dial-back - mistakes can be easily

Children frequently make mistakes when self-administering insulin. A device 
that makes the process easier and simpler will help them avoid errors, improve 
their dose dialing accuracy, and give them greater confidence.

"T1D is often difficult. It takes an emotional toll. It is life-threatening. 
And it never goes away," said Julien Oakes, a person living with T1D. "But we 
can learn to successfully manage the disease, and with the support of 
resources such as JuniorSTAR(™), we can get on with living a normal life and 
achieving our goals."

About Sanofi Sanofi, a global healthcare leader, discovers, develops and 
distributes therapeutic solutions focused on patients' needs. Sanofi has core 
strengths in the field of healthcare with seven growth platforms: diabetes 
solutions, human vaccines, innovative drugs, consumer healthcare, emerging 
markets, animal health and the new Genzyme. Sanofi is listed in Paris 
(EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi entities in Canada include Sanofi Canada (pharmaceuticals), Sanofi 
Pasteur (vaccines), Sanofi Consumer Health (cosmeceuticals, over-the-counter 
products and specialty care), Genzyme (rare diseases) and Merial (animal 
health). Together they employ close to 1,700 people across the country. In 
2013 Sanofi companies invested $125,1 million in R&D in Canada, creating jobs, 
business and opportunity throughout the country. www.sanofi.ca

Follow Sanofi Canada on Twitter @SanofiCanada.

Video and photos are available on request. Go to starsystem.sanofi.ca for 
further information. 

SOURCE  Sanofi Canada 
For interviews, contact: Toronto, Niki Kerimova, office: 416-777-0368, cell: 
647-278-3375, niki@prpost.ca; Montreal, Lamia Charlebois, office: 
514-279-4601, cell.: 514-581-5831, rp@lamiacharlebois.com 
To view this news release in HTML formatting, please use the following URL: 
CO: Sanofi Canada
ST: Quebec
-0- Jul/02/2014 13:47 GMT
Press spacebar to pause and continue. Press esc to stop.